A new CDC report dismisses the connection between thimerosal-containing vaccines and autism, just days before a contentious advisory meeting. With new committee members and rising concerns, the health debate intensifies!
A document from the Department of Health and Human Services backing Secretary Kennedy's vaccine policy change has been criticized by health experts for misrepresenting studies and spreading disinformation about the safety of Covid vaccines for children and pregnant women.
In a bold move, Health Secretary Robert F. Kennedy Jr. announces eight new members to the CDC's vaccine advisory committee, some of whom have previously criticized vaccines, raising eyebrows and concerns about future recommendations.
In a bold and controversial move, Health Secretary Robert F. Kennedy Jr. has dismissed the entire vaccine advisory panel, raising concerns about the future of immunization recommendations and public health trust.
HHS Secretary Robert F. Kennedy Jr. has dismissed the entire vaccine advisory panel, citing conflicts of interest. This unprecedented move raises concerns about vaccine safety and public health integrity.
In a bold move, HHS Secretary Robert F. Kennedy Jr. removes all members of the CDC's vaccine advisory committee, aiming to restore public trust in vaccine science. Critics warn this could undermine decades of progress in public health.
In a recent interview, FDA Commissioner Marty Makary sparked controversy by urging Americans to consult their doctors regarding Covid-19 vaccines, citing mixed data on their safety for children and pregnant individuals. As the government alters vaccine recommendations, public health experts express concern over potential risks.
In a groundbreaking move, the FDA has approved Moderna's lower-dose Covid-19 vaccine for older adults and at-risk individuals. Get ready for a new option this fall as Moderna targets the LP.8.1 variant!
Robert F. Kennedy Jr. canceled a critical $766 million contract with Moderna for a bird flu vaccine, raising concerns about public health and vaccine safety amidst a potential outbreak.
The U.S. has approved Moderna's new COVID-19 vaccine, mNexspike, specifically for high-risk groups. This innovative option offers a lower dose while maintaining effectiveness, marking a pivotal step in the fight against coronavirus.
